Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum MetabolitesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether rifaximin, a poorly absorbed antibiotic known for regulating gut microbiota, could improve loperamide-induced constipation. The researchers assessed effects on serum neurotransmitters and neuropeptides, water-channel gene expression, inflammation-related gene expression, gut microbiota composition, and serum metabolomics. The goal was to clarify how rifaximin might act on the gut-microbiota axis to relieve constipation.
Who was studied?
The study used Sprague-Dawley (SD) rats in which constipation was experimentally induced with loperamide. No human cohort was involved, as this was a preclinical animal model study. Sample size and group numbers were not specified in the abstract.
What were the most important findings?
Rifaximin improved constipation by increasing serum 5-HT and substance P (SP) and by raising mRNA expression of the water-channel genes AQP3 and AQP8, while reducing expression of the inflammation-related genes TLR2 and TLR4. It also reshaped the gut microbiota of constipated rats, increasing potentially beneficial bacteria Akkermansia muciniphila and Lactobacillus murinus while reducing Bifidobacterium pseudolongum. Metabolomics analysis showed that serum metabolites altered by constipation, including bile acids and steroids, were restored toward normal levels after rifaximin treatment.
What are the greatest implications of this study?
The findings suggest rifaximin could serve as a multi-target therapy for functional constipation, acting through gut microbiota modulation, water metabolism, neurotransmitter and neuropeptide signaling, and reduced intestinal inflammation. The multi-omics approach highlights specific bacterial taxa and metabolite classes, such as bile acids, as potential mechanistic links between microbiota changes and constipation relief. These results support further investigation of rifaximin as a microbiome-targeted intervention for constipation, pending confirmation in human studies.